Yet, these studies usually only included BRAF V600E and V600K [Combi-D (dabrafenib/trametinib) [4••] and Columbus (encorafenib/binimetinib) [3••] or only BRAF V600E [CoBRIM (vemurafenib/cobimetinib) [9••] mutated melanomas. Here, BRAF is linked to melanoma.